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ABSTRACT 
Hexavalent chromium, or Cr(VI), is a potent oxidizer and known carcinogen, that 
is found at varying levels in the water sources of more than 200 million Americans. 
However, the exact mechanism of carcinogenicity remains unknown, and though the 
government currently regulates total chromium levels, they have yet to determine a 
permissible exposure limit for Cr(VI). Moreover, there is currently no preventative 
treatment for Cr(VI). Because of Cr(VI)’s strong oxidative power, we hypothesized that it 
causes DNA mutation and cell death via oxidation and that antioxidants could prevent 
this from occurring. To test this, we first assessed the viability of human cell culture 
exposed to Cr(VI) with or without either of the antioxidants vitamin C or 
epigallocatechin gallate (EGCG). Further, an Ames test was performed to determine the 
mutagenicity of Cr(VI) with and without either antioxidant.  
We found that Cr(VI) is significantly toxic to cell culture at concentrations of 200 
ppb (parts per billion) or more. Both vitamin C and EGCG blocked this effect at 10 ppm 
(parts per million) and 15 ppm, respectively, while neither antioxidant was observed to 
be cytotoxic when treated alone. Cr(VI) was also found to be significantly mutagenic at 
20 ppb and greater. This mutagenicity was significantly reduced by cotreatment with 20 
ppm vitamin C at 200 and 2000 ppb Cr(VI), while vitamin C was not found to be 
mutagenic when tested individually. With these combined data, we conclude that Cr(VI) 
is both cytotoxic and mutagenic via an oxidative mechanism and these effects can be 
abrogated by antioxidants. Though continued study is merited, this information further 
validates the protective potential of antioxidants against toxicants like Cr(VI). 
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INTRODUCTION 
Hexavalent Chromium 
The toxicological effects of hexavalent chromium (Cr(VI)) compounds have been 
widely studied over the years. Specifically, data have been collected to assess its 
carcinogenic effects on humans through case study (Yu, 2013), and its toxicological 
effects on rats (Geetha et al., 2003) and cell cultures (Majone et al., 2002). Though there 
exist three different oxidative states for chromium, the hexavalent form has been found 
to be much more toxic than the quadrivalent form or the trivalent form, which is in fact 
an essential element for humans (Sun et al., 2015). Unfortunately, the toxicant can be 
found in hexavalent form in the tap water of nearly two thirds of the United States’ 
drinking supply (Andrews & Walker, 2016). Though the environmental protection 
agency (EPA) monitors total chromium levels in drinking water, hexavalent levels are not 
monitored, and the toxicant is ingested daily. The EPA’s current maximum contaminant 
level for total chromium is 100 ppb, yet it is unclear if Cr(VI) at 100 ppb could have 
detrimental effects on a population. In humans, hexavalent chromium toxicity through 
ingestion has been known to cause cardiovascular, gastrointestinal, hematological, 
hepatic, renal, and neurological damage, and in severe cases, causes cancer or death 
(Yu, 2013).  
Chromium is a naturally occurring element and often found at low levels in both 
the hexavalent and trivalent states in natural watersheds (Loyaux-Lawniczak et al., 
2001). However, chromium compounds are often used for chromium plating and other 
industrial uses and can elevate these low levels (Kamerud et al., 2013). Disposal of 
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chromium containing commercial products and coal ash from electric utilities are major 
sources of chromium releases into the soil. Solid waste and slag produced during 
chromate manufacturing processes can be potential sources of chromium exposure as 
well (Barceloux 1999). Improper disposal and maintenance of Cr(VI) at these facilities 
can cause environmental contamination and drinking water pollution (Cone, 2009). A 
recent study done of Illinois water showed that hexavalent chromium concentrations 
were actually higher in treated water than those in untreated water. Indeed, Cr(VI) 
levels on surface water were found to be 0.3 ppb, and levels in bedrock aquifers at 1.1 
ppb, whereas those in treated water supplies were 2.4 ppb, indicating that water 
treatment practices may ironically play a role in increasing concentrations (Mills & Cobb, 
2015). Though these levels are well below the EPA-regulated limit, it is still unknown 
whether these levels are detrimental to human health. 
Mechanism of Toxicity 
The mechanism of toxicity of Cr(VI) has been found to be induction of oxidative 
stress, which further leads to cell toxicity and cell death (Bagchi et al., 2002; Chiu et al., 
2010). In their study, Martindale & Holbrook found that oxidative stress results when 
reactive oxygen species (ROS), either produced endogenously as a consequence of 
normal cellular functions or derived from external sources, cause damage that exceeds 
the cell’s ability to resist oxidation (Martindale & Holbrook, 2002). They went on to find 
that when ROS originate from exogenous sources, they are either taken up directly by 
cells from the extracellular matrix or produced as a consequence of the cell's exposure 
to an environmental antagonist, such as Cr(VI). Transient fluctuations in ROS serve 
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important regulatory functions such as in aerobic respiration, but when present in high 
levels, ROS can cause severe damage to DNA, protein, and lipids. A number of cellular 
defense mechanisms have evolved to combat the accumulation of ROS. These include 
various non‐enzymatic molecules such as glutathione, and vitamins A, C, and E, as well 
as enzymatic scavengers of ROS like superoxide dismutase and catalase (Martindale & 
Holbrook, 2002). Unfortunately, these systems of defense are not always adequate to 
counteract the production of ROS, resulting in what is termed a state of oxidative stress. 
Because of its 6+ oxidation state, Cr(VI) is a potent oxidizer that can challenge the limited 
capacity of natural antioxidative systems.  
Ames Assay 
Previous research shows that not only are hexavalent chromium compounds 
carcinogenic, but they are also directly mutagenic towards deoxyribonucleic acid (DNA) 
(Petrilli & Deflora, 1976). In this study, a genetically engineered strain of Salmonella 
typhimurium was exposed to differing solutions to test mutagenic potential. When 
exposed to a mutagen, this specific strain of bacteria will revert from a state of 
auxotrophy (inability to produce the essential amino acid histidine), to a state of 
prototrophy (ability to produce histidine). This genetic reversion allows the bacteria to 
survive and replicate, whereas a lack of mutation will result in death. Bacterial survival, 
observed by colorimetric determination of its growth media, is therefore a direct 
indicator of DNA mutagenesis. This same study showed that the mutagenic effects were 
caused directly by Cr(VI) and not due to a metabolic byproduct within the bacteria 
(Petrilli & Deflora, 1976). This information therefore indicated that not only is Cr(VI) 
 
 
4 
 
toxic to organisms but is also directly mutagenic toward cellular DNA, with a 
preventative treatment yet to be elucidated. 
Reduction Potential 
Different approaches have been utilized to reduce the oxidizing potential of 
Cr(VI). For example, one study showed that the use of certain microorganisms as 
biological filters could be used to lower chromium levels (Thatoi et al., 2014), while 
several others have shown that antioxidants are effective (Chrysochoou & Reeves, 2016; 
Geetha et al., 2003). Antioxidants lower the oxidation state of chromium from 
hexavalency to the lower, less harmful state of trivalency. One study showed that 
epigallocatechin gallate (EGCG) directly reduces Cr(VI) in solution (Chrysochoou & 
Reeves, 2013), whereas another showed that vitamin C also reduces Cr(VI) in solution 
and in the past has been used as a topical treatment against Cr(VI) skin exposure (Yu, 
2013). A third study tested the effect of antioxidants extracted from the plant 
Hippophae rhamnoides on albino rats when co-fed with hexavalent chromium. Results 
suggested that rats that had been fed antioxidants along with the chromium compounds 
exhibited declines in tumor growth both in size and frequency compared to those 
without antioxidants (Geetha et al., 2003). Though this study demonstrates that a plant 
extract with antioxidant properties prevents Cr(VI)-induced toxicity at the organismal 
level, little is known about the effects of specific antioxidants at the cellular level. To 
date, there have been no studies of Cr(VI) and antioxidant cotreatment on human cell 
culture, and though antioxidants are known to reduce Cr(VI), there is still uncertainty in 
regard to which antioxidants are most effective. Additionally, the extent to which 
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antioxidants are protective has yet to be elucidated; whether they protect against 
cytotoxicity upon the cell membrane and within the cytoplasm, or if they protect against 
mutagenesis within the nucleus as well. We hypothesized that when co-treated with an 
antioxidant, hexavalent chromium would exhibit less cytotoxicity on a human cell 
culture. We also hypothesized that when co-treated with an antioxidant, hexavalent 
chromium would exhibit less mutagenicity towards bacterial DNA. 
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METHODS 
Cell culture, compounds, and storage 
Human intestinal epithelial (HInEpi) cells were obtained from the American Type 
Culture Collection (ATCC) and were sustained on the cell line’s respective ATCC media. 
Human embryonic kidney (HEK) cells were obtained from a secondary passage in 
nitrogen storage in house at Reed Hall of Science, though the original passage was 
obtained from Dr. Seth Robia (Loyola University Chicago). These cells were sustained on 
Dulbecco’s Modified Eagle Medium with 10% Fetal Bovine Serum, 1% Penicillin-
Streptomycin, and 1% L-Glutamine, all of which were sourced from Sigma Aldrich. Cells 
were incubated at 37°C and 5% CO2 and passaged once confluent using trypsin-EDTA. 
Both L-ascorbic acid and epigallocatechin gallate were obtained from Sigma Aldrich. The 
Cr(VI) compound used for experimentation was potassium chromate, also obtained 
from Sigma Aldrich. 
Determination of treatment concentration 
Experimental Cr(VI) concentrations were tested in magnitudes of 10 ranging 
from 2 ppb (parts per billion) to 20,000 ppb to simulate environmental conditions as 
well as coincide with previous literature. These concentrations were used for both cell 
proliferation and Ames procedures. Antioxidant concentrations were determined 
through experimentation, starting at a 1:1 ratio of antioxidant to Cr(VI) and adjusted 
accordingly based on response until effects were seen.  
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Solution Preparation 
Stock solutions of Cr(VI), EGCG, and ascorbic acid were prepared by dissolving 
solute in double-distilled water at a concentration of 2000 ppm and then filter 
sterilizing. Once treatment concentrations had been determined as described above, 
smaller aliquots of stock solution were mixed with the appropriate cell media to bring 
the final mixture to the desired experimental concentration. Experimental solution 
containing both Cr(VI) and an antioxidant for cotreatment were prepared by bringing 
both a Cr(VI) solution and an antioxidant solution to twice their desired final 
concentration in media and then adding the two solutions together to dilute the sample 
down to its experimental concentration. Stock solutions were stored at 4°C and were 
remade several times throughout experimentation to avoid expiration. Experimental 
solutions were made within 24 hours of use. 
Cellular proliferation assay 
Both the HInEpi and HEK cells were passaged in T-75 flasks in respective media 
until confluency was reached. These cells were then passaged onto a 24-well plate and 
again cultured until wells reached confluence. Treatment groups were then run in 
quadruplicate, allowing for six sample groups per plate that were exposed to solution 
for 72 hours. To depict qualitative results, photos were taken of wells at points of 
interest along the way using a Nikon TXI inverted microscope with phase contrast. 
After the 72-hour incubation period, media was aspirated and cells were 
trypsinized and suspended in solution. 10 μl of solution were taken from each well and 
 
 
8 
 
mixed with equal parts Trypan blue. After at least a minute to allow for cell staining to 
occur, 10 μl of cell suspension/trypan stain solution were drawn off and dispensed over 
a hemocytometer for counting of viable cells to determine number of cells per 
treatment group.  
Ames assay 
Ames test kits were purchased from Environmental Bio-detection Products Inc. 
(EBPI), and the assay was carried out according to manufacturer’s instructions. The 
lyophilized bacterial culture was suspended in a liquid medium (Reagent G) 12 to 16 
hours prior to experimentation. Once suspended, the bacteria were placed in a shaking 
incubator at 37°C to replicate and grow overnight. The following day, experimental 
samples were prepared by diluting the Cr(VI) stock solution in sterile water to desired 
concentrations. Turbidity within the bacterial culture verified growth, and the OD600 of 
the solution was measured by spectrophotometry. This OD (optical density) value was 
then used to bring the bacterial suspension to a desired concentration through a series 
of calculations (Appendix 1). Three samples of each treatment group were placed in a 
24-well plate for the bacterial exposure period. Positive, negative, and sterility controls 
were also included on the exposure plate. Added into each well was the treatment 
solution, exposure media, and the bacterial suspension, and the plate was incubated at 
37°C for 100 minutes. During the incubation period, a reversion medium was prepared 
for the 96-well plates. After the bacteria had been incubated for 100 minutes, the plate 
was removed and solution from each well was pipetted into a tube containing the 
premade reversion medium. Using loading boats and a multichannel pipette, each 
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sample was pipetted into 48 wells of a 96-well plate. The 96-well plates were then 
placed in an incubator at 37°C for 3 days to allow for revertant bacteria to grow. After 
the 3 day incubation period, plates were scored by colorimetric determination with 
yellow and partial-yellow wells indicating genetic reversion. 
Statistical analysis 
The statistical analysis for both the cell proliferation data and the Ames assay 
data were done by a two-tailed t-test data with p-values < 0.05 determined to be 
statistically significant. The error bars depicted in the figures below show standard error 
of the mean. 
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RESULTS 
 
To determine if antioxidants could prevent Cr(VI)-induced cytotoxicity, we first 
had to establish Cr(VI) toxicity without cotreatment with antioxidants. This also helped 
us determine a good concentration of Cr(VI) to use for cotreatment. HEK cells exposed 
to increasing concentrations of Cr(VI) displayed a marked reduction of cell viability. 
Figure 1 shows that Cr(VI) levels of 1000 ppb completely eradicated all cells in the 
treatment group. These data indicate not only the severity of Cr(VI) exposure but also 
provide a basis for a range of exposure doses and cellular susceptibility.  For this study, 
we chose to use 500 ppb Cr(VI) as an intermediate dose to elucidate the potency of the 
antioxidants vitamin C and EGCG.  
Figure 1: Human embryonic kidney cells display reduced viability upon increasing exposure 
to Cr(VI). HEK cells were exposed to different doses of Cr(VI) ranging from 200      ppb to 
1000 ppb. A negative dose response to Cr(VI) was observed. 
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Next, we wanted to determine if the presence of vitamin C could prevent Cr(VI)-
induced cytotoxicity. To test for this, chromium concentrations were kept constant at 
500 ppb while varying concentrations of vitamin C were added as cotreatment. 50 ppm 
vitamin C was also run independently as a control group and yielded similar cell counts 
as the negative control, indicating a lack of cellular toxicity of vitamin C alone. Figure 2 
shows that 500 ppb Cr(VI) cotreated with as little as 5 ppm vitamin C more than doubled 
the cells per well from 500 ppb Cr(VI) alone. Furthermore, responses were observed in a 
dose dependent manner in wells cotreated with 10 and 25 ppm vitamin C. Importantly, 
there was no significant difference observed between 500 ppb Cr(VI) cotreated with 25 
ppm vitamin C and the negative control.  
These results were also replicated qualitatively upon a second cell line. Human 
Intestinal epithelial cells were exposed to the same treatment groups as the above 
Figure 2: The antioxidant vitamin C can prevent toxicity of Cr(VI). Human embryonic kidney 
cells were exposed to cotreated samples of 500 ppb Cr(VI) and differing concentrations of 
vitamin C. Likelihood of survival increased with the addition of vitamin C. Cr(VI) was 
completely mitigated by 25 ppm vitamin C.  
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mentioned HEK cells. Due to difficulties in the cell counting procedure for this particular 
line of cells, representative pictures of treatment groups were taken to serve as 
alternative results to quantification. As shown in Figure 3, cotreatment with 25 ppm 
vitamin C markedly improved cytotoxic effects of 500 ppb Cv(VI). Together, these data 
suggest that Cr(VI) toxicity and the protective effect of vitamin C can be broadly applied 
across different cell types. 
Not only were we interested in the protective potential of vitamin C, but 
antioxidants at large. To test this theory, we exposed HEK cells to solutions cotreated 
with 500 ppb Cr(VI) and varying concentrations of EGCG to compare the efficacy of the 
two antioxidants (Figure 4). As in the case of vitamin C, EGCG demonstrated protective 
effects in a dose dependent manner starting at 7.5 ppb EGCG. However, unlike the 
complete protection from Cr(VI) toxicity that was observed with vitamin C at a lower 
dose, even the highest dose of EGCG was only able to protect approximately 60% of the 
HEK cells. 
Figure 3: Vitamin C protects human intestinal epithelial cells from Cr(VI)-induced 
cytotoxicity. Cells were exposed to untreated cell media (panel A), as well as 500 ppb Cr(VI) 
(panel B) and 500 ppb Cr(VI) cotreated with 25 ppm vitamin C (panel C). Cotreatment 
mitigated nearly all observed effects of Cr(VI). This result was replicated on human 
embryonic kidney cells. These images were taken 3 days after exposure. 
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We next wanted to test the protective potential of antioxidants against Cr(VI)-
induced mutagenicity. To test this, bacteria were exposed to Cr(VI) as well as Cr(VI) 
cotreated with vitamin C in an Ames assay. Figure 5 shows that as Cr(VI) concentrations 
increased from 20 ppb to 2000 ppb, percent mutagenicity increased. Treatment groups 
of 20, 200, and 2000 ppb were significantly more mutagenic than the negative control. 
Cotreatment with 20 ppm vitamin C significantly reduced the mutagenicity of 200 ppb 
and 2000 ppb Cr(VI). Moreover, 20 ppm vitamin C was not found to be mutagenic itself.  
 
  
Figure 4: The antioxidant EGCG can prevent toxicity of Cr(VI). Human embryonic kidney cells 
were exposed to solutions of 500 ppb Cr(VI) cotreated with varying concentrations of EGCG. 
As EGCG concentrations increased, cell survival also increased. 
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Figure 5: Bacterial cells cotreated with vitamin C and Cr(VI) exhibit less mutagenesis than 
those without the antioxidant. Bacterial cultures exposed to solution containing higher 
levels of Cr(VI) were more likely to mutate DNA. Those exposed to high levels of Cr(VI) as 
well as vitamin C were less likely to mutate. * denotes p-value < 0.05 when compared to 
negative control, ** denotes p-value < 0.005 when compared to negative control, # denotes 
p-value < 0.05 compared to that concentration of Cr(VI) alone. The positive control is a 12.5 
ppb sodium azide solution. 
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DISCUSSION 
After exposing human cell cultures to a range of Cr(VI) concentrations, we 
observed that increasing concentrations of Cr(VI) was associated with cell death of both 
HEK and HIE cells (Figures 1 & 3).  However, we found that the detrimental effects of 
Cr(VI) were mitigated by the addition of the antioxidants vitamin C or EGCG in a dose 
dependent manner (Figures 2 and 4). This evidence suggests that Cr(VI) is indeed 
cytotoxic via an oxidative mechanism, as the presence of an antioxidant reduced 
cytotoxicity. 
Vitamin C was found to be a much more potent protective chemical than EGCG 
(Figures 2 and 4). This could be due to the vast difference in the size of the two 
molecules, as ascorbic acid is much smaller than its counterpart. It’s unclear where the 
reduction of Cr(VI) into Cr(III) is occurring, whether inside the cell in the cytoplasm or 
outside the cell within the culture media, though it is probable that the majority is 
occurring in the media before the toxicant enters the cell. This is because the Cr(VI) was 
exposed to the antioxidant in solution hours before being dispensed over the cells. 
Indeed, metabolic clearance of Cr(VI) may likewise occur prior to cellular interaction. 
Roughly ten percent of inorganic Cr(VI) is absorbed through the intestinal tract (Yu, 
2013). Excretion of absorbed chromium occurs primarily via urine. In humans, the 
kidney excretes about 60% of an absorbed Cr(VI) dose in the form of Cr(III) within 8 
hours of ingestion. Approximately 10% of an absorbed dose is eliminated by biliary 
excretion, with smaller amounts excreted in hair, nails, milk, and sweat (Kiilunen & 
Kivisto, 1983). Therefore, a majority of the reduction interactions occurring between 
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antioxidants and Cr(VI) likely take place before the two components enter the cell. 
However, while clearance from plasma is generally rapid (within hours), whereas 
elimination from tissues is slower, with a half-life of several days (ATSDR, 2012). 
Data from the Ames assay further suggests that Cr(VI) is indeed mutagenic by 
way of oxidation. Though previous studies have shown that Cr(VI) is mutagenic (Petrilli 
& Deflora, 1976), the novel cotreatment with antioxidants performed in this study show 
that chemical reduction decreases mutagenicity, indicating that the oxidative 
mechanism of Cr(VI) plays a critical role in mutagenesis. As bacterial strains were 
exposed to increasing concentrations of the toxicant, percent mutation increased as 
well. When exposed to solution cotreated with antioxidant, however, percent mutation 
was essentially nullified as levels were brought back down to those observed within the 
negative control group, regardless of the concentration of Cr(VI). That is, any group 
treated with vitamin C exhibited no significant change from the negative control, even 
at the highest concentration of Cr(VI) (2000 ppb). 
Furthermore, neither antioxidant tested was found to be cytotoxic or mutagenic 
in-and-of-itself. Thus, they may serve as a preventative protectant as pre-treatment 
within a drinking water supply. We cannot pre-treat the water with a level of protectant 
so high that it itself becomes a harmful contaminant. This concern is needless in this 
case as both vitamin C and EGCG showed great protective potential at levels at which 
they themselves were harmless. 
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It appears that Cr(VI) is more mutagenic towards bacterial DNA at lower 
concentrations (20 ppb) than it is cytotoxic towards mammalian cells (200 ppb). This 
result may suggest two things. One reason for this discrepancy may be that bacterial 
cells are more sensitive to Cr(VI); this is probably a result of the vast differences 
between prokaryotic and eukaryotic cells. Eukaryotes have several other cellular 
components that Cr(VI) may interact with before reaching the DNA within the nucleus. 
The second conclusion may be that mutagenicity is also occurring in the mammalian 
cells at concentrations similar to that in the bacteria, but that the mutations occurring 
are nonlethal or nonharmful. This would be a reasonable assumption, as a mammalian 
eukaryotic cell has far more DNA than a prokaryotic bacterium (Alberts et al., 2015). 
Additionally, a prokaryotic genome has fewer regions of noncoding DNA (20%) than that 
of a eukaryote (98%) (Alberts et al., 2015). Therefore, there is a greater likelihood that a 
mutagen would affect a critical region in the bacterial genome, while eukaryotic cells are 
afforded a degree of insulation by vast noncoding stretches of DNA that can absorb 
mutagens such as Cr(VI). In either case, this merits further research into Cr(VI) 
mutagenicity in a mammalian cell line.  
This study focused only on the cotreatment of antioxidants with Cr(VI) as 
opposed to pre-treatment or post-treatment. Specifically, both bacterial cells in the 
Ames test and human cells in the cell proliferation assay were exposed to both the 
toxicant and the protectant simultaneously. In both assays, the cotreated solution was 
prepared 1 to 10 hours before cell exposure. Because of this, the chemical interaction 
taking place between the two compounds likely occurs in solution. An interesting 
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continuation of this study would be examining the differences between a cotreatment 
with antioxidant (as performed in this study) and a pre or post-treatment with 
antioxidant. This would provide information as to whether antioxidants could protect 
against impending Cr(VI) exposure or help cells recover from prior Cr(VI) exposure. 
These assays would also shed more light as to where the majority of the chemical 
reduction of the chromium is occurring, either in solution or within the cells themselves. 
These data come at a time when hundreds of millions of Americans are exposed 
to hexavalent chromium in their daily water supply (Andrews & Walker, 2016). The 
protective potential of antioxidants is promising, and applications of this research are 
numerous. For example, just as many European countries began adding fluoride to 
public water supplies in the early 90s to prevent dental caries, antioxidants may be 
useful additions to water supplies known to have higher concentrations of Cr(VI) or 
areas at higher risk of Cr(VI) contamination. Moreover, these findings suggest that 
antioxidants as reducing agents may also be applied in mitigation of other harmful 
oxidizers. Though continued study is merited, this information further validates the 
protective potential of antioxidants and will be helpful for government agencies and 
organizations in determining safe levels of water chromium.  
  
 
 
19 
 
REFERENCES 
Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., Walter, P. (2015). 
Molecular Biology of the Cell; sixth edition. Garland Science, Taylor & Francis 
Group, LLC. 
Ames, B., Durston, W., Yamasaki, E., & Lee, F. (1973). Carcinogens are Mutagens: A 
Simple Test System Combining Liver Homogenates for Activation and Bacteria for 
Detection. Proceedings of the National Academy of Sciences USA, 70(8), 2281-
2285. 
Andrews, D., & Walker, B. (2016). ‘Erin Brockovich’ Carcinogen in Tap Water of more 
than 200 Million Americans. Environmental Working Group. 
ATSDR, Agency for Toxic Substances and Disease Registry. (2012). Toxicological Profile 
for Chromium. 
Bagchi, D., Stohs, S.J., Downs, B.W., Bagchi, M., & Preuss, H.G. (2002). Cytotoxicity and 
Oxidative Mechanisms of Different forms of Chromium. Toxicology, 180, 5-22. 
Barceloux, D. G. (1999). Chromium. Toxicology, 37(2), 173-94. 
Casarett, L. J., Klaassen, C. D., Amdur, M. O., & Doull, J. (1996). Casarett and Doull's 
Toxicology: The Basic Science of Poisons. New York: McGraw-Hill, Health 
Professions Division. 
 
 
20 
 
Chiu, A., Shi, J., Hill, R., Katz, A., (2010). Review of Chromium (VI) Apoptosis, Cell-Cycle-
Arrest, and Carcinogenesis. Environmental Science Health Ecotoxicology Review., 
28(3), 188–230 
Chrysochoou, M., & Reeves, K. (2016). Reduction of Hexavalent Chromium by Green Tea 
Polyphenols and Green Tea Nano Zero-Valent Iron. Bulletin of Environmental 
Contamination and Toxicology, 98(3), 353-358. 
Cone, M. (2009). Chromium in Drinking Water Causes Cancer. Environmental Health 
News, (February, 20).  
Dalcin, M.G., Pirete, M.M., Lemos, D.A., Ribeiro, E.J., Cardoso, V.L., & Resende, M.M. 
(2011). Evaluation of Hexavalent Chromium Removal in a Continuous Biological 
Filter with the use of Central Composite Design. Journal of Environmental 
Management, 92(4), 1165-1173. 
Division of Public Water Supplies. (2011). Assessment of Total Chromium in Illinois 
Community Water Supplies. Illinois Environmental Protection Agency. 
Geetha, S., Sai Ram, M., Mongia, S., Singh, V., Ilavazhagan, G., & Sawhney, R. (2003). 
Evaluation of Antioxidant Activity of Leaf Extract of Seabuckthorn (Hippophae 
rhamnoides) on Chromium(VI) Induced Oxidative Stress in Albino Rats. Journal of 
Ethnopharmacology, 87(2-3), 247-251. 
 
 
21 
 
Kamerud, K.L., Hobbie, K.A., & Anderson, K.A. (2013). Stainless Steel Leaches Nickel and 
Chromium into Foods during Cooking. Journal of Agricultural and Food 
Chemistry, 61, 9495-9501. 
Kiilunen, M., & H. Kivisto, (1983). Exceptional Pharmacokinetics of Trivalent Chromium 
During Occupational Exposure to Chromium Lignosulfonate Dust. Scandinavian 
Journal of Work, Environment & Health 9(3), 265-71. 
Levis, A.G., Bianchi, V., Tamino, G., & Pegoraro, B. (1978). Cytotoxic Effects of 
Hexavalent and Trivalent Chromium on Mammalian Cells in Vitro. Br. J. Cancer, 
37, 386-396. 
Loyaux- Lawniczak, S., Lecomte, P., & Ehrhardt, J.J. (2001). Behavior of Hexavalent 
Chromium in a Polluted Groundwater: Redox Processes and Immobilization in 
Soils. Environmental Science and Technology, 35(7), 1350-1357. 
Majone, F., Bianchi, V., Dal Toso, R., Debetto, P., Levis, A.G., Luciani, S., & Tamino, G. 
(2002). Mechanisms of Chromium Toxicity in Mammalian Cell Cultures. 
Toxicology, 17(2), 219-224. 
Martindale, J. L., & Holbroook, N. J. (2002). Cellular response to oxidative stress: 
Signaling for suicide and survival. Journal of Cellular Physiology, 192(1), 1-15. 
Mills, P.C., & Cobb, R.P. (2015). Hexavalent and Total Chromium at Low Reporting 
Concentrations in Source-Water Aquifers and Surface Waters Used for Public 
 
 
22 
 
Supply in Illinois. U.S. Geological Survey Scientific Investigations Report 2015–
5020, 58. 
Oze, C., Bird, D.K., & Fendorf, S. (2007). Genesis of Hexavalent Chromium from Natural 
Sources in Soil and Groundwater. Proceedings of the National Academy of the 
Sciences, 104(16), 6544-6549. 
Petrilli, F., & DeFlora, S. (1976). Toxicity and Mutagenicity of Hexavalent Chromium on 
Salmonella typhimurium. Applied and Environmental Microbiology, 33(4), 805-
809. 
Strober, W. (2001). Trypan Blue Exclusion Test of Cell Viability. National Institute of 
Allergy and Infectious Diseases, 3, 10.1002. 
Sun, H., Brocato, J., & Costa, M. (2015). Oral Chromium Exposure and Toxicity. Curr 
Environmental Health Report, 2, 295–303. 
Thatoi, H., Das, S., Mishra, J., Rath, B.P., & Das, N. (2014). Bacterial Chromate Reductase, 
a Potential Enzyme for Bioremediation of Hexavalent Chromium: A Review. 
Journal of Environment Management, 146, 383-399. 
Von Burg, R. (1993). Chromium and Hexavalent Chromium. Journal of Applied 
Toxicology, 13(3), 225-230. 
Yu, D. (2013). Chromium Toxicity. Agency for Toxic Substances and Disease Registry. 
  
 
 
23 
 
Appendix 
 
1. X = OD600 measurement for overnight bacteria, Y = Working concentration (For 
this specific strain, TA100, the working concentration is 0.05 at OD600), Final 
volume = 6 mL. 
 
Volume of overnight bacteria (mL) required for dilution = 
𝒀
𝑿
× Final volume 
 
Example: TA100 was grown overnight and recorded an OD600 = 0.65 
 
Volume of TA100 required for dilution = 
𝟎.𝟎𝟓
𝟎.𝟔𝟓
× 6 = 0.46 mL 
 
Therefore, 0.46 mL of overnight bacterial solution will be added to 5.54 ml of 
Reagent N to bring the final volume to 6 mL. 
 
